Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) to a strong-buy rating in a report published on Monday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Inhibikase Therapeutics presently has an average rating of “Moderate Buy”.

Inhibikase Therapeutics Stock Performance

Shares of NASDAQ IKT opened at $1.44 on Monday. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $4.20. The firm has a market capitalization of $108.26 million, a P/E ratio of -3.69 and a beta of 0.88. The business’s 50 day simple moving average is $1.56.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.